The Clinical Significance and Prognostic Role of Whole-Blood Epstein-Barr Virus DNA in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis
Authors:
- 24 April 2023
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 43 (6) , 1302-1310
Abstract
Purpose To evaluate the role of circulating Epstein-Barr virus (EBV) DNA in lymphoma-associated hemophagocytic lymphohistiocytosis (HLH). Methods We conducted a retrospective cohort study to explore the clinical and prognostic significance of EBV DNA in lymphoma-associated HLH. We included adult patients with combined diagnoses of lymphoma and HLH from January 2010 and November 2022 by retrieving the medical record system. Results A total of 281 patients with lymphoma-associated HLH were identified. Elevated whole-blood EBV DNA was observed in 54.4% (153/281) of patients, and the median copy number was significantly higher in the T/NK-cell malignancies (199,500, interquartile range, 30,000–1,390,000) than that in the B-cell non-Hodgkin lymphoma (5520, interquartile range, 1240–28,400, P < 0.001). The optimum cutoff for predicting survival was 16,100 copies/mL. Compared to the patients with EBV DNA ≤ 16,100 copies/mL, those with EBV DNA > 16,100 copies/mL were younger and had more T/NK-cell malignancies, lower levels of neutrophils and fibrinogen, and higher levels of hemoglobin, alanine aminotransferase, aspartate aminotransferase, lactic dehydrogenase, and β2-microglobulin. A higher load of EBV DNA (> 16,100 copies/mL), thrombocytopenia (< 100 × 109/L), neutropenia (< 1 × 109/L), hypofibrinogenemia (≤ 1.5 g/L), and elevated levels of creatinine (> 133 μmol/L) were independent adverse predictors of 60-day overall survival and overall survival. A prognostic index based on EBV DNA and the other four factors was established to categorize the patients into four groups with significantly different outcomes. Conclusion Our study identified high EBV load as a risk factor for lymphoma-associated HLH and established a prognostic index to predict outcomes.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (82100207, 81720108002)
- Natural Science Foundation of Jiangsu Province (BK20210962)
- Translational research grant of NCRCH (2020ZKZB01)
This publication has 26 references indexed in Scilit:
- Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trialHaematologica, 2019
- Pathogenic Gene Mutations or Variants Identified by Targeted Gene Sequencing in Adults With Hemophagocytic LymphohistiocytosisFrontiers in Immunology, 2019
- Innovative analysis of predictors for overall survival from systemic non-Hodgkin T cell lymphoma using quantile regression analysisChinese Medical Journal, 2019
- The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated with Dose-Adjusted EPOCHCancer Research and Treatment, 2019
- Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNABlood Cancer Journal, 2017
- EBV-negative Aggressive NK-cell Leukemia/LymphomaAmerican Journal of Surgical Pathology, 2017
- PEG-aspargase and DEP regimen combination therapy for refractory Epstein–Barr virus-associated hemophagocytic lymphohistiocytosisJournal of Hematology & Oncology, 2016
- Prognostic impact of Epstein-Barr virus (EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemiaOncotarget, 2015
- Epstein–Barr virus (EBV) DNA in whole blood as a superior prognostic and monitoring factor than EBV-encoded small RNA in situ hybridization in diffuse large B-cell lymphomaClinical Microbiology and Infection, 2015
- Haemophagocytic lymphohistiocytosis, interferon‐gamma‐naemia and Epstein‐Barr virus involvementBritish Journal of Haematology, 1994